home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 01/04/22

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatm...
RUBY - Rubius to report additional Phase 1 data for RTX-240 in solid tumors next quarter

Updating the progress of its clinical pipeline ahead of its first Pipeline and Platform Day, Rubius Therapeutics (NASDAQ:RUBY) said that additional data from its early-stage trial for off-the-shelf cellular therapy candidate RTX-240 are expected in Q1 2022. RTX-240 is undergoing a Phase 1 tri...

RUBY - Rubius Therapeutics to Highlight the Power of its RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Highly Versatile and Programmable RED PLATFORM Enables Multiple Modalities to Target Different Immune Pathways Across a Range of Diseases Demonstrated Tolerance Induction with Bystander Suppression in Type 1 Diabetes Preclinical Program with Findings Translatable to Multiple T Cell-Me...

RUBY - Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
RUBY - Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Places to Work in Rhode Island by Providence Business News

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatme...

RUBY - Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatme...

RUBY - Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatme...
RUBY - Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for Immunotherapy of Cancer's Annual Meeting

CAMBRIDGE Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatmen...

RUBY - Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius’ Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advanced Solid Tumors and Relapsed/Refractory...

RUBY - Rubius Therapeutics to Announce Third Quarter 2021 Financial Results

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the tr...
Previous 10 Next 10